To investigate the effect of tigecycline on intracranial infection of extensively drug-resistant Acinetobacter baumannii (XDRAB) by dual approach.

The 30 patients with intracranial infection of XDRAB admitted to the Neurosurgery Department of PLA 81^st Army Hospital from October 2016 to October 2021 were selected as research objects. The subjects were divided into experimental group and control group according to random number table method, with 15 cases in each group. The experimental group (15 cases) was treated with tigecycline. Tigecycline was administered 100 mg intravenously (once every 12 h), lumbar puncture or lumbar cistern drainage was performed to release cerebrospinal fluid, and intrathecal injection of 4 mg tigecycline with the concentration of 1 mg/mL was administered once a day. The control group (15 cases) was treated with meropenem (2 g, once every 8 h) and cefoperazone sulbactam (3 g, once every 8 h) and lumbar puncture or lumbar cistern drainage was performed to release cerebrospinal fluid. Various indicators of cerebrospinal fluid and the therapeutic efficacy were compared between the two groups before and after treatment.

After 4 weeks of treatment, the number of white blood cells and the levels of protein in the cerebrospinal fluid of the experimental group were lower than the control group, meanwhile glucose levels in the cerebrospinal fluid of the experimental group were higher than the control group, the the differences between the groups were statistically significant (P<0.05). The cure rate of the experimental group (73.3%) was higher than the control group (40.0%) (P<0.05). No serious adverse reactions were found in both groups.

Dual approach tigecycline treatment of XDRAB intracranial infection can significantly improve the indicators of cerebrospinal fluid and improve the cure rate of patients, and achieve good clinical efficacy, worthy of clinical application.